Levopropoxyphene

DB06793ApprovedWithdrawnSmall molecule

Levopropoxyphene is a stereoisomer of propoxyphene in the form of 2S, 3R enantiomer. It was sold as an antitussive, but it was removed from the market in the 70s. Levopropoxyphene... Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962.

Chemical structure of Levopropoxyphene
Primary indication
Levopropoxyphene was used as an antitussive.Curator reviewed
Formula / weight
C22H29NO2 · 339.479 g/mol (avg)
Also known as
(l)-Propoxyphene

Resolves to

Compound
UNIIU75VZ9PK1JCAS2338-37-6ChEMBLCHEMBL1738990ChEBI51174PubChem200742
Clinical / RWD
RxNorm6377
Structure
InChIKeyXLMALTXPSGQGBX-PGRDOPGGSA-NSMILES[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1
Targets
P35372OPRM1

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
89Drug interactionsStructured to mechanism, not free text
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Levopropoxyphene, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In